In conclusion, the platinum resistance of SKOV3 ovarian cancer cells may be different in terms of its refractoriness to cisplatin treatment according to the level of HOXB9 overexpression and the subsequently induced expression of ERCC-1, MRP-2, and XIAP, as well as Bcl-2/Bax expression. This evidence concerns the gene BCL2 and ovarian carcinoma.